1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Turkey >
  5. Amgen Acquires Mustafa Nevzat Pharmaceuticals

M&A Deal Summary

Amgen Acquires Mustafa Nevzat Pharmaceuticals

On April 25, 2012, Amgen acquired life science company Mustafa Nevzat Pharmaceuticals for 700M USD

Acquisition Highlights
  • This is Amgen’s 11th transaction in the Life Science sector.
  • This is Amgen’s 13th largest (disclosed) transaction.
  • This is Amgen’s 1st transaction in Turkey.

M&A Deal Summary
Date 2012-04-25
Target Mustafa Nevzat Pharmaceuticals
Sector Life Science
Buyer(s) Amgen
Deal Type Add-on Acquisition
Deal Value 700M USD
Advisor(s) BofA Securities (Financial)
Paksoy (Legal)

Target

Mustafa Nevzat Pharmaceuticals

Istanbul, Turkey
MN Pharmaceuticals is the oldest pharmaceutical company in Turkey. The company was established in 1923 in a district of İstanbul known as Üsküdar, İhsaniye under the name of Mustafa Nevzat Laboratory. With its 8 employees, the 'Laboratory' was one of the first manufacturers of injectable products in Turkey.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States
Category Company
Founded 1980
Sector Life Science
Employees28,000
Revenue 33.4B USD (2024)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 12 of 21
Sector: Life Science M&A 11 of 20
Type: Add-on Acquisition M&A Deals 12 of 20
Country: Turkey M&A 1 of 1
Year: 2012 M&A 3 of 4
Size (of disclosed) 13 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-04-10 KAI Pharmaceuticals

South San Francisco, California, United States

KAI Pharmaceuticals is a life science company based in South San Francisco. KAI's lead product candidate KAI-4169 is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.

Buy $315M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-12-10 deCODE genetics

Reykjavik, Iceland

deCODE genetics is a population-based genomics company conducting research into the inherited causes of common diseases. Together with pharmaceutical companies and other healthcare institutions, deCODE aims to utilize its research to develop new methods for identifying, treating and preventing disease.

Buy $415M
Mergr

Solution for

Product

Company

Legal